The Lancet Commission on prostate cancer: planning for the surge in cases

作者：Nicholas D. James, Ian F. Tannock, James N’Dow, Felix Y. Feng, Silke Gillessen, Syed Adnan Ali, Blanca Trujillo, Bissan Al‐Lazikani, Gerhardt Attard, Freddie Bray, Éva Compérat, Rosalind A. Eeles, Omolara Fatiregun, Emily Grist, Susan Halabi, Áine Haran, Daniel Herchenhorn, Michael S. Hofman, Mohamed Jalloh, Stacy Loeb, Archie Macnair, Brandon A. Mahal, Larissa Mendes, Masood Moghul, Caroline M. Moore, Alicia K. Morgans, Michael J. Morris, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, Anwar R. Padhani, Charles Parker, Hannah Rush, Mark Sculpher, Howard R. Soule, Matthew R. Sydes, Derya Tilki, Nina Tunariu, Paul Villanti, Liping Xie · 发表于：The Lancet · 年份：2024 · DOI：10.1016/s0140-6736(24)00651-2 · 被引用次数：718 · 研究领域：Prostate Cancer Diagnosis and Treatment、Prostate Cancer Treatment and Research、Global Cancer Incidence and Screening

Executive summaryProstate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers.In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy.Our findings suggest that the number of new cases annually will rise from 1•4 million in 2020 to 2•9 million by 2040.This surge in cases cannot be prevented by lifestyle changes or public health interventions alone, and governments need to prepare strategies to deal with it.We have projected trends in the incidence of prostate cancer and related mortality (assuming no changes in treatment) in the next 10-15 years, and make recom mendations on how to deal with these issues.For the Commission, we established four working groups, each of which examined a different aspect of prostate cancer: epidemiology and future projected trends in cases, the diagnostic pathway, treatment, and management of advanced disease, the main problem for most men diagnosed with prostate cancer worldwide.Throughout we have separated problems in highincome countries (HICs) from those in lowincome and middle income countries (LMICs), although we acknowledge that this distinction can be an oversimplification (some rich patients in LMICs can access highquality care, whereas many patients in HICs, especially the USA, cannot because of inadequate insurance coverage).The burden of disease globally is already substantial, but options to improv...